Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Reports Third Quarter 2026 Financial Results

Maravai LifeSciences reported Q3 2026 revenue of $45.9 million, up 10.1% year-over-year, with mRNA product revenue up 28%. Adjusted EBITDA swung to $5.8 million from $(10.8) million a year ago, though the company posted a GAAP net loss of $(24.0) million, or $(0.09) per Class A share. Management raised full-year 2026 guidance to $212.0-$216.0 million in revenue and $40.0-$42.0 million in Adjusted EBITDA, citing four Discovery mRNA customers transitioning to clinical-stage GMP.

•4d ago

TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP

TriLink BioTechnologies, a Maravai LifeSciences (NASDAQ: MRVI) subsidiary, was granted a new Chinese patent covering CleanCap cap analog compounds themselves and mRNA pharmaceutical compositions. This is TriLink's second CleanCap patent in China in months, adding composition-of-matter protection on top of earlier method-of-synthesis claims to create a multi-layered IP asset. The broader IP position supports TriLink's licensing business; CleanCap is used in approved COVID-19 mRNA vaccines and numerous development programs.

•1mo ago

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Maravai LifeSciences reported Q2 2026 revenue of $51.4 million, up 8.5% year-over-year, with Adjusted EBITDA turning positive to $8.7 million compared to a loss in the prior year. The company raised its full-year 2026 Adjusted EBITDA guidance to a range of $33 million to $35 million, up from the previous range of $30 million to $32 million, while reiterating its revenue guidance of $205 million to $215 million. Segment performance was led by TriLink, which grew 11.5% year-over-year driven by strong demand for Discovery and GMP consumables, while Cygnus delivered 3% growth marking its fifth consecutive quarter of positive growth.

•3mo ago

TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences, has been granted a new patent in China covering its CleanCap capping analogs and methods for synthesizing RNA molecules. The patent, issued by the China National Intellectual Property Administration, expands the global intellectual property footprint for CleanCap technology, covering trimer or tetramer capping structures used in mRNA production. Management noted that this addition reinforces the company's position as the sole authorized manufacturer and supports its strategy of maintaining strong IP coverage across all major jurisdictions.

•3mo ago

TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale

TriLink BioTechnologies, part of Maravai LifeSciences, opened a GMP enzyme manufacturing facility in Jupiter, Florida, designed to support integrated IVT supply from R&D to commercial scale. The facility offers a coordinated, single-source package of enzymes, nucleotides, and cap analogs, aiming to simplify sourcing and reduce manufacturing risks for RNA developers. The company successfully shipped its first commercial GMP enzyme batch in June 2026, featuring the CleanScribe RNA Polymerase which reduces double-stranded RNA formation by up to 85%.

•4mo ago

Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

Maravai LifeSciences refinanced its credit agreement, establishing a $150 million term loan and a $30 million revolving credit facility. The company used the new term loan plus $98.5 million in cash to prepay its prior debt, reducing total principal from $242.9 million to $150 million. This move extends the maturity date to June 2032, strengthening the balance sheet and preserving liquidity for future growth.

•5mo ago

Maravai LifeSciences Reports First Quarter 2026 Financial Results

Maravai LifeSciences reported Q1 revenue of $65.8 million, up 41% year-over-year, driven by a 65% surge in TriLink revenue. The company returned to positive free cash flow with $4.2 million generated and posted Adjusted EBITDA of $20.3 million, compared to a loss in the prior year. Management raised full-year 2026 guidance, now expecting revenue of $205.0M-$215.0M and Adjusted EBITDA of $30.0M-$32.0M, up from the prior EBITDA range of $18.0M-$20.0M.

•6mo ago